[Form 4] Catheter Precision, Inc. Insider Trading Activity

Rhea-AI Filing Summary

James Joseph Caruso, a director of Catheter Precision, Inc. (VTAK), reported an option award on 08/12/2025. The filing shows an acquisition of 50,000 stock options with an exercise price of $0.18. The options are exercisable beginning 08/12/2025 and reference an 08/12/2035 date in the derivative table, with the filing stating the options vest one-third per year beginning on the first anniversary of the grant. After this transaction Caruso beneficially owns the 50,000 underlying shares directly. The form is signed 08/14/2025.

Positive

• 50,000 options granted to a director, aligning interests with shareholders
• Clear vesting schedule: vests one-third per year beginning on first anniversary, supporting retention
• Low exercise price disclosed ($0.18), making the grant's cost basis explicit

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director option grant of 50,000 options at a low exercise price; limited immediate market impact.

The grant of 50,000 options at $0.18 aligns management incentives with shareholder value but appears routine for executive/director compensation. The vesting schedule (1/3 per year after the first anniversary) ties long-term retention to performance horizon. There is no financial statement or revenue data in this filing, so material valuation impact cannot be assessed from this form alone. For investors, this is a governance/compensation disclosure rather than an operational development.

Corporate Governance Expert

TL;DR: Standard equity-based compensation disclosure for a director; suggests retention incentive but not a red flag.

The Form 4 documents a granted option package with multi-year vesting, a common practice to retain directors. The direct beneficial ownership of 50,000 underlying shares is disclosed clearly. The filing includes required dates and signature, meeting Section 16 reporting obligations. No departures, accelerated exercises, or related-party complexity are present in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caruso James Joseph

(Last) (First) (Middle)

1670 HIGHWAY 160 WEST

SUITE 205

(Street)

FORT MILL SC 29708

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Catheter Precision, Inc. [ VTAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$0.18	08/12/2025		A		50,000		(1)	08/12/2035	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Options vests 1/3 per year beginning on first anniversary of grant date.

	/s/ James Joseph Caruso	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for VTAK and what is their role?

The report was filed by James Joseph Caruso, who is identified as a Director of Catheter Precision, Inc.

What securities transaction is reported on this Form 4 for VTAK?

The filing reports acquisition of 50,000 stock options with an exercise price of $0.18 on 08/12/2025.

What is the vesting schedule for the options reported in the VTAK Form 4?

The options vest one-third per year beginning on the first anniversary of the grant date.

How many shares does the reporting person beneficially own after the transaction?

After the reported transaction, the filing shows beneficial ownership of the 50,000 underlying shares directly.

When was the Form 4 signed and filed?

The signature on the Form 4 is dated 08/14/2025.